Synapse - Works

Results (2899)

Lisocabtagene maraleucel (LISO‐CEL) versus standard of care (SOC) as second‐line therapy in large B‐cell lymphoma (TRANSFORM study): Subgroup analyses by prior therapy response

Meeting Abstract

Nastoupil, L. J.; Kamdar, M.; Chavez, J. C.; Ghesquieres, H.; Ghosh, M.; Holmes, H.; López‐Guillermo, A.; Martínez‐López, J.; Novak, U.; Ribrag, V.; more...
Hematological Oncology (2023)

Fulltext@MSK | Save

Impact of response to systemic bridging therapy on clinical outcomes and cytokine profile in patients receiving CAR T‐cell therapy for aggressive B‐cell lymphoma

Meeting Abstract

Wills, B.; Shouval, R.; Flynn, J.; Devlin, S. M.; Shah, G. L.; Scordo, M.; Dahi, P. B.; Lin, R. J.; Imber, B.; Parascondola, A.; more...
Hematological Oncology (2023)

Fulltext@MSK | Save

Bispecific anti‐CD20/19 CAR‐T—zamtocabtagene autoleucel for relapsed/refractory DLBCL—Interim analysis results of DALY‐II‐USA study

Meeting Abstract

Ulrickson, M.; Miklos, D. B.; Maziarz, R. T.; Jacobson, C.; Isufi, I.; Ghosh, M.; Perales, M.; Lunning, M.; Hardy, N. M.; Wijatyk, A.; more...
Hematological Oncology (2023)

Fulltext@MSK | Save

Durables responses with anti‐CD19 allogeneic CAR T ALLO‐501/501A in phase 1 trials of relapsed/refractory large B‐cell lymphoma (R/R LBCL)

Meeting Abstract

Locke, F. L.; Lekakis, L.; Eradat, H.; Munoz, J.; Tees, M.; de Vos, S.; Nath, R.; Stevens, D.; Malik, S.; Popplewell, L.; more...
Hematological Oncology (2023)

Fulltext@MSK | Save

Dynamics of radiomic features following bridging therapy determine CD19 chimeric antigen receptor (CAR) T‐cell therapy outcome

Meeting Abstract

Imber, B. S.; Silverman, E. A.; Leithner, D.; Hubbeling, H.; Shah, G. L.; Fregonese, B.; Sanin, B. W.; Tomas, A. A.; Parascondola, A.; Saldia, A.; more...
Hematological Oncology (2023)

Fulltext@MSK | Save

Primary overall survival analysis of the phase 3 randomized ZUMA‐7 study of axicabtagene ciloleucel versus standard of care in relapsed/refractory large B‐cell lymphoma

Meeting Abstract

Westin, J. R.; Oluwole, O. O.; Kersten, M. J.; Miklos, D. B.; Perales, M. A; Ghobadi, A.; Rapoport, A. P.; Sureda, A.; Jacobson, C. A.; Farooq, U.; more...
Hematological Oncology (2023)

Fulltext@MSK | Save

Allogeneic transplant following CAR T-cell therapy for large B-cell lymphoma

Journal Article

Zurko, J.; Ramdial, J.; Shadman, M.; Ahmed, S.; Szabo, A.; Iovino, L.; Tomas, A. A.; Sauter, C.; Perales, M. A.; Shah, N. N.; more...
Haematologica (2023)

Fulltext@MSK | Save

Inaccuracies in assignment of patient race and ethnicity: Implications for unrelated donor searches and health care delivery

Research Letter

Fingrut, W. B.; Davis, E.; Chinapen, S.; Naputo, K.; Politikos, I.; Scaradavou, A.; Barker, J. N.
Blood Advances (2023)

Fulltext@MSK | Save

A multicenter phase II, double-blind, placebo-controlled trial of maintenance ixazomib after allogeneic transplantation for high-risk multiple myeloma: Results of the Blood and Marrow Transplant Clinical Trials Network 1302 trial

Journal Article

Bashir, Q.; Nishihori, T.; Pasquini, M. C.; Martens, M. J.; Wu, J.; Alsina, M.; Anasetti, C.; Brunstein, C.; Dawson, P.; Efebera, Y.; more...
Transplantation and Cellular Therapy (2023)

Fulltext@MSK | Save

Osteonecrosis of the jaw associated with pembrolizumab

Journal Article

Pennings, I.; Moskowitz, A.; Shah, G.; Estilo, C.; Huryn, J. M.; Yom, S. K.
Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology (2023)

Fulltext@MSK | Save